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 1 
MANUSCRIPT   1 
 2 
Structured summary  3 
 4 
Objectives - Although difficult to clinically diagnose, presumptive meningomyelitis 5 
of unknown origin (MMUO) is an important differential diagnosis for dogs presenting 6 
with signs of spinal cord dysfunction. The aim of this study was to evaluate clinical 7 
presentation, diagnostic findings and long-term outcome for dogs clinically diagnosed 8 
with MMUO.  9 
Methods - Medical records were reviewed for dogs diagnosed with presumptive 10 
MMUO between 2006 and 2015.  11 
Results - Twenty-one dogs met the inclusion criteria. The majority of dogs presented 12 
with an acute (43%) or chronic (52%) onset of neurological signs. Ambulatory paresis 13 
was the most common neurological presentation (67%). Neurological examination 14 
most commonly revealed a T3-L3 myelopathy, and spinal hyperaesthesia was a 15 
common finding (71%). A spinal cord lesion was visible in 90% of cases on MR 16 
imaging. Lesions were typically extensive, ill-defined, hyperintense on T2-weighted 17 
and isointense on T1-weighted images. Eighteen lesions (86%) showed parenchymal 18 
contrast enhancement and 17 lesions (81%) showed contrast enhancement of 19 
overlying meninges. All dogs were treated with immunosuppressive doses of 20 
glucocorticosteroids, sometimes combined with cytosine arabinoside. At time of data 21 
capture, 10/21 dogs (48%) had died or been euthanized because of MMUO. Overall 22 
median survival time was 669 days.  23 
Impact - MMUO should be considered in the differential diagnosis of dogs 24 
presenting with an acute or chronic, progressive, and potentially painful myelopathy. 25 
 2 
MRI features can possible help to distinguish presumptive MMUO from other more 26 
common spinal diseases. Overall, long-term survival is guarded, approximately 50% 27 
of dogs will die or be euthanized because of MMUO regardless of 28 
immunosuppressive treatment.  29 
 30 
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Introduction  34 
Pure myelitis (inflammation of spinal cord parenchyma) or meningomyelitis 35 
(inflammation of spinal cord parenchyma and surrounding meninges) are rare 36 
diseases in small animals and occur commonly in combination with inflammatory 37 
brain disease (Tipold and Stein 2010). Viruses (canine distemper virus, feline 38 
coronavirus), bacteria (Staphylococcus spp., Streptococcus spp., Pasteurella, 39 
coliforms, Actinomyces, Nocardia spp.), fungi (Cryptococcus, Coccidioides spp., 40 
Blastomyces, Histoplasma), rickettsiae (Ehrlichia, Rickettsia, Rocky Mountain 41 
spotted fever), protozoa (Toxoplasma gondii, Neospora caninum), parasites 42 
(Dirofilaria immitis, Cuterebra, Angiostrongylus vasorum) and algae (Prototheca 43 
wickerhamii, Prototheca zopfii) are known causes for meningomyelitis in dogs and 44 
cats, with or without concurrent intracranial signs (Dewey 2016; Csebi et al. 2010; 45 
Parry et al. 2009; Griffin et al. 2008). Apart from infectious causes, non-infectious 46 
meningomyelitis including granulomatous meningoencephalomyelitis, 47 
pyogranulomatous meningoencephalomyelitis and steroid-responsive meningitis-48 
arteritis (SRMA) are described (Dewey 2016; Parry et al. 2009; Griffin et al. 2008; 49 
Meric 1988). In agreement with the terminology for meningoencephalitis of unknown 50 
origin (MUO), dogs clinically diagnosed with non-infectious inflammatory myelitis 51 
that did not have positive infectious disease testing, that were not classified as SRMA 52 
or eosinophilic meningomyelitis, and that were not histopathologically confirmed, 53 
were named meningomyelitis of unknown origin (MMUO). A clinical diagnosis of 54 
MMUO is typically made by a combination of clinical presentation, imaging of the 55 
vertebral column, and results of cerebrospinal fluid (CSF) analysis (Griffin et al. 56 
2008).  57 
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Currently, only one previous study has focused specifically on the clinical 58 
presentation, diagnostic findings, and outcome in dogs with meningomyelitis caused 59 
by a variety of underlying aetiologies (Griffin et al. 2008). Twenty-eight cases were 60 
included, of which 15 dogs were diagnosed with MMUO. Clinical signs were 61 
reflected by the affected spinal cord segments, and younger dogs, toy breeds, and 62 
hound breeds were suggested to be predisposed for meningomyelitis. Although results 63 
of myelography, computed tomography (CT), and CT-myelography have been 64 
reported, little is known about magnetic resonance imaging (MRI) findings in dogs 65 
with MMUO. The aims of this study were therefore to describe the signalment, 66 
clinical presentation, diagnostic findings, including results of MRI, and long-term 67 
survival in dogs diagnosed with presumptive MMUO without concurrent clinical 68 
signs of intracranial (Deleted: It was hypothesized that dogs diagnosed with MMUO 69 
could be of any breed, gender or age, that they would present generally with severe 70 
neurological dysfunction but without spinal hyperaesthesia and that their long-term 71 
prognosis is guarded to good).  72 
 73 
 74 
 75 
Materials and methods 76 
Case selection  77 
The electronic medical database was searched between March 2006 and February 78 
2015 for dogs diagnosed with “MUA”, “MUO”, “GME”, “myelitis”, “inflammatory 79 
spinal cord disease”. Dogs were included based on the criteria used by Granger et al. 80 
(2010), if they had (1) complete medical records available, (2) a complete 81 
neurological examination performed leading to a spinal cord localisation, (3) 82 
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inflammatory CSF analysis, (4) MRI of the spinal cord, and if (5) long-term follow-up 83 
information was available through revision of medical records or through contacting 84 
the referring veterinarian by telephone. Dogs were excluded if (1) the clinical records 85 
or imaging studies were incomplete or not available for review, (2) dogs showed 86 
clinical or neurological signs of intracranial involvement at time of presentation, (3) 87 
they had a peracute onset of clinical signs that were not progressive after 12-24 hours, 88 
(4) they had signs of extradural or extradural/intramedullary spinal cord compression 89 
on MRI and if (5) they had positive infectious disease titres or if clinical presentation, 90 
CSF analysis or necropsy findings were suggestive of SRMA or eosinophilic 91 
meningoencephalomyelitis (>10% eosinophils in CSF) (Dewey 2016). Typical 92 
clinical presentation for SRMA was considered to be a dog less than 2 years of age of 93 
a typical dog breed (Boxer, Beagle, Bernese Mountain dog, Nova Scotia Duck Tolling 94 
Retriever, Golden Retriever, German Shorthaired Pointed) presenting with pyrexia 95 
and cervical hyperesthesia. CSF analysis in SRMA is typically revealing a 96 
predominantly neutrophilic pleocytosis (Dewey 2016). Dogs with histopathological 97 
confirmation of the disease (granulomatous meningo(encephalo)myelitis (GMEM) or 98 
necrotising meningo(encephalo)myelitis (NMEM)) only needed to fulfil inclusion 99 
criteria (1) and (5). Information retrieved from the medical records included breed, 100 
gender, age at diagnosis, body weight, results of neurological examination including 101 
neuroanatomical localisation, duration of clinical signs prior to diagnosis, results of 102 
complete blood count (CBC) and biochemistry profile, results of CSF analysis 103 
including total nucleated cell count (TNCC), white blood cell differentiation and total 104 
protein (TP) concentration, treatment received, and outcome. (Deleted: Based on body 105 
weight, dogs were divided in small/medium (<15kg) and large breed dogs (>15kg). 106 
For dog breeds in which the body weight varied around 15kg, mean body weight for 107 
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male and female dogs as reported on the Kennel Club website 108 
(http://www.thekennelclub.org.uk/services/public/breed/standard-find.aspx) were 109 
used to consider them large or medium/small breed dogs). Duration of clinical signs 110 
prior to diagnosis (days) was classified as peracute (<2 days), acute (2–7 days) or 111 
chronic (>7 days). For dogs that had CSF analysis performed, site of collection 112 
(cisternal or lumbar), TNCC, TP and cytological differentiation were recorded. Total 113 
nucleated cell count was considered normal if < 5 cells/mm3. Protein concentration 114 
was considered normal for a cisternal collection if < 0,25 g/l and for a lumbar 115 
collection if < 0,4 g/l.  116 
 117 
Neurological assessment 118 
The neurological status was classified from 0 to 5 according to the clinical 119 
examination (adapted from Scott et al. 1997): grade 0 = neurologically normal; grade 120 
1 = spinal hyperesthesia without neurological deficits; grade 2 = ataxia, ambulatory 121 
para- or tetraparesis; grade 3 = non- ambulatory para- or tetraparesis; grade 4 = para- 122 
or tetraplegia with or with- out bladder control, and intact deep pain sensation; grade 123 
5 = para- or tetraplegia, urine retention or overflow, and deep pain sensation loss.  124 
Possible neuroanatomical localizations included C1-C5, C6-T2, T3-L3 or L4-S3 125 
spinal cord segments. Dogs were diagnosed with a focal lesion if only one spinal cord 126 
segment was affected, and with a multifocal lesion if more then one spinal cord 127 
segment appeared to be affected on the neurological examination.  128 
 129 
Magnetic resonance imaging 130 
Magnetic resonance imaging was performed under general anaesthesia with a 131 
permanent 1.5T magnet (Intera, Philips Medical Systems, Eindhoven, the 132 
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Netherlands) and all images were reviewed by the corresponding author using Osirix 133 
Dicom viewer (Osirix Foundation, V.5.5.2 Geneva, Switzerland). Sequences could 134 
vary, but studies included a minimum of T2-weighted (T2W) (repetition time (ms) 135 
(TR)/echo time (ms) (TE), 3000/120) and T1-weighted (T1W) (TR/TE, 400/8) images 136 
of the affected spinal cord region in a sagittal and transverse plane. The T1W images 137 
were acquired before and after IV administration of paramagnetic contrast medium 138 
(0,1 mg/kg, gadoterate meglumine, Dotarem, Guerbet). If MR images of the brain 139 
were present, they were reviewed concurrently. Variables recorded were lesion 140 
intensity on T2W and T1W images, lesion localization and distribution, lesion length 141 
and presence of parenchymal and/or meningeal contrast enhancement. Lesion length 142 
was measured using Osirix Dicom viewer, and performed on sagittal T2W images for 143 
dogs that had focal lesions. Lesion length was measured twice, and the mean value 144 
between both was used. To compensate for differences in body size, values were 145 
corrected towards length of vertebral body of C6 (for cervical lesions) or L2 (for 146 
thoracolumbar lesions). Vertebral body length was measured on T1W sagittal images.  147 
 148 
Treatment and follow-up 149 
For all dogs, the specific treatment protocol was recorded. During hospitalisation, all 150 
dogs underwent daily at least one general physical and complete neurological 151 
examination by a board-certified neurologist or neurology resident. The results of the 152 
neurological examination as well as response to treatment (improvement, 153 
deterioration or static status) were systematically recorded on the kennel sheets. 154 
Follow-up information during hospitalisation was collected from the medical records, 155 
and afterwards through medical records of re-examination visits or telephone contact 156 
with the referring veterinarian. A successful outcome was defined as the dog being 157 
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ambulatory, fecal and urinary continent and, according to the owners, without signs of 158 
overt spinal hyperaesthesia. An unsuccessful outcome was defined as (1) deterioration 159 
in neurological status by one or more grades after diagnosis and treatment, or (2) if 160 
the dog was not independently ambulatory, possibly with previously non-existing or 161 
worsening fecal and/or urinary incontinence, or was experiencing spinal 162 
hyperaesthesia as defined by the owner. 163 
 164 
Statistical analysis 165 
Data analysis was performed with the aid of a standard statistical software package 166 
(Prism, Graphpad Software Inc). (Deleted: A Mann-Whitney U test was used to 167 
compare age, duration of clinical signs prior to diagnosis, and TNCC in CSF between 168 
small/medium and large breed dogs. A fisher’s exact test was used to compare 169 
differences in sex and neuroanatomical localization between small/medium and large 170 
breed dogs.) Regarding outcome, a Mann-Whitney U test was used to evaluate effect 171 
of relative lesion length on long-term outcome. A fisher’s exact test was used to 172 
evaluate the effect of pain, presence of lymphopenia and additional administration of 173 
cytosine arabinoside on outcome. Numeric variables were expressed as median and 174 
interquartile ranges (IQR). Values of P<0.05 were considered significant. Survival 175 
analysis was performed using both a Log-rank (Mantel-Cox) and Gehan-Breslow-176 
Wilcoxin test, resulting in median survival time (MST) calculation and a Kaplan-177 
Meier survival curve. (Deleted: comparing survival percentage in small/medium and 178 
large breed dogs, and presenting overall survival 179 
 One-way NOVA was used to evaluate significant differences between affected 180 
regions on neurological examination.) Survival was defined as time from diagnosis to 181 
death or euthanasia, including whether this happened because of disease progression 182 
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or due to unrelated causes, or time from diagnosis to data collection for dogs that 183 
were alive at time of data capture. Dogs that died because of unrelated causes and 184 
dogs that were still alive at time of data capture were censored for survival analysis.  185 
 186 
Results 187 
Signalment 188 
Twenty-one dogs were included in the study. (Deleted: Thirteen dogs (62%) were 189 
large breeds and 8 dogs (38%) were considered small/medium breed dogs) 190 
Represented breeds included French Bulldog (n=2), Jack Russell Terrier (n=2), Lhasa 191 
Apso (n=2) and one each of Akita, Bearded Collie, Boxer, Bull Mastiff, Chihuahua, 192 
cross breed, English Springer Spaniel, Giant Schnauzer, Labrador Retriever, Maltese 193 
Terrier, Rhodesian Ridgeback, Rottweiler, Shih Tzu, West Highland White Terrier 194 
and Yorkshire Terrier. Overall, median age at presentation was 56 months (10 – 128 195 
months). (Deleted: There was no significant difference in age at presentation between 196 
small/medium and large breed dogs (P=0.358).)Thirteen dogs (62%) were male and 8 197 
dogs (38%) were female. Compared to the general hospital population between March 198 
2006 and February 2015, there was no significant difference in sex distribution in the 199 
group of dogs with MMUO (P=0.075). Median duration of clinical signs prior to 200 
diagnosis was 8 days (ranging from 1-90 days). One dog (5%) presented with 201 
peracute, 9 dogs (43%) with acute and 11 dogs (52%) with a chronic onset of 202 
neurological signs.  203 
 204 
Neurological examination 205 
Thirteen (62%) and 8 (38%) dogs were diagnosed with a focal and multifocal spinal 206 
lesion on neurological examination, respectively. (Deleted: Small/medium breed dogs 207 
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presented significantly more with a focal spinal cord lesion on the neuroanatomical 208 
localisation compared to large breed dogs (P=0.049).) Regarding dogs with focal 209 
spinal lesions (n=13), 3 dogs were diagnosed with a lesion affecting the C1-C5 spinal 210 
cord segments, 2 dogs with a lesion affecting the C6-T2 spinal cord segments, 6 dogs 211 
with a lesion affecting the T3-L3 spinal cord segments and 2 dogs with a lesion 212 
affecting the L4-S3 spinal cord segments. At time of diagnosis, no dogs presented as 213 
grade 0; 2 dogs (10%) were grade 1; 14 dogs (67%) grade 2; and 5 dogs (24%) grade 214 
3. No dogs were found to have paraplegia or tetraplegia at time of presentation. Pain 215 
on direct spinal palpation was present in 15 (71%) dogs. Urinary retention was seen in 216 
2 dogs (10%), and a combination of urinary and faecal incontinence was noticed in 2 217 
dogs (10%). One dog (5%) developed seizures 669 days after diagnosis of MMUO. 218 
An overview of the clinical findings of the 21 included dogs, can be consulted in table 219 
1.  220 
 221 
Diagnostic findings 222 
As required by the inclusion criteria, CSF collection revealed a pleocytosis in all 223 
cases. Overall, median TNCC was 209 cells/mm3 (ranging from 6 – 6000). Total 224 
protein measurement was performed in all but 3 CSF samples, and was above 225 
reference values in 17/18 dogs (94%). The median TP concentration was 1.67 g/l 226 
(ranging from 0.21-16.3 g/l). Complete blood count and serum biochemistry results 227 
were available in 16 dogs (76%). Leucocytosis was only present in 2 dogs (10%) and 228 
lymphopenia was present in 6 dogs (29%). Infectious disease testing based on 229 
serology and/or polymerase chain reaction (PCR) on CSF for Canine Distemper Virus 230 
(CDV), Toxoplasma gondii, and Neospora caninum was not performed in 2 (10%) 231 
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dogs and was negative in the remaining 19 (90%) dogs. In the 2 dogs with lacking 232 
infectious disease testing, full necropsy was performed, revealing GMEM.  233 
 234 
Magnetic resonance imaging 235 
Magnetic resonance imaging of the spinal cord was available in all cases, revealing a 236 
focal lesion in 15 dogs (71%), a multifocal lesion in 4 dogs (19%) and no lesion was 237 
visible on sagittal T2W or T1W images in 2 dogs (10%). Lesion length was measured 238 
in the focal cases only. Median lesion/vertebral body ratio was 4.8 (ranging from 0.6 239 
– 10.9). All visible lesions were ill-defined, intramedullary, hyperintense on T2W 240 
images and isointense on T1W images (Figure 1 and 2). Lesions showed parenchymal 241 
contrast enhancement in 18 dogs (86%), and contrast enhancement of overlying 242 
meninges in 17 dogs (81%). In dogs presenting with spinal hyperaesthesia (n= 15), 243 
there was no significant association with the presence of meningeal contrast 244 
enhancement on MRI (P=0.24). In the 2 cases where no lesion was visible on sagittal 245 
T2W and T1W images, no parenchymal contrast enhancement was seen, but 1 dog 246 
only showed meningeal contrast enhancement. In 2 dogs (10%) intracranial images 247 
were present within the field of view of the cervical spinal cord images (T2W 248 
transverse and sagittal images), revealing multiple T2W hyperintensities in the 249 
forebrain and/or brainstem. Neither of those dogs had clinical or neurological signs of 250 
intracranial involvement at time of diagnosis. The first dog, a 56-month-old Jack 251 
Russell Terrier, never recovered from general anaesthesia after diagnostic procedures, 252 
and full necropsy revealed GMEM. The second dog, a 123-month-old Rhodesian 253 
Ridgeback, developed seizures 669 days after diagnosis and was euthanized without 254 
further investigations.  255 
 256 
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Treatment and outcome  257 
As required by the inclusion criteria, outcome was available in all dogs. As described 258 
above, one dog never recovered from general anaesthesia for MRI of the spinal cord, 259 
and this dog was censored for survival analysis. Mean duration of hospitalisation was 260 
5 days (ranging from 1 – 19 days), with 17 dogs (81%) showing improvement in 261 
neurological status within those days. One dog (5%) remained neurologically stable 262 
(no improvement nor deterioration), and 3 dogs (14%) showed deterioration of their 263 
neurological status. All dogs, including the dog that never recovered from 264 
anaesthesia, were treated with immunosuppressive doses of glucocorticosteroids 265 
immediately after diagnosis. This consisted of IV dexamethasone (dose ranging from 266 
0.3 – 0.5 mg/kg/day) in 9 dogs (43%), and oral prednisolone (dose ranging from 2 – 4 267 
mg/kg/day) in 12 dogs (57%). Fourteen dogs (67%) received additional treatment 268 
with cytosine arabinoside as a constant rate infusion (CRI) of 200mg/m2 over 8 hours 269 
in 1 dog (7%) and as 4 subcutaneous (SC) injections of 50mg/m2 every 12 hours for 2 270 
consecutive days in 13 dogs (93%).  271 
Twenty dogs (95%) survived to discharge. Of these dogs, 9 dogs (45%) were still 272 
alive at time of data capture. Of these 9 dogs, 8 dogs were neurologically normal 273 
according to follow-up information, and 1 dog was still showing ataxia and 274 
ambulatory paraparesis. Of the 8 normal dogs, 2 dogs were still receiving 275 
cyclosporine 5mg/kg every 24 hours, 1 dog was receiving cytosine arabinoside 50mg/ 276 
m2 every 12 hours for 2 consecutive days every 9 weeks, 1 dog was receiving 277 
prednisolone 0.2mg/kg every 24 hours, 1 dog was receiving prednisolone 1mg/kg 278 
every 24 hours and cytosine arabinoside 50mg/ m2 every 12 hours for 2 consecutive 279 
days every 4 weeks, and 3 dogs were not receiving any treatment at time of data 280 
capture. The dog that was still showing neurological abnormalities was receiving 281 
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0.5mg/kg prednisolone every other day and cytosine arabinoside 50mg/ m2 every 12 282 
hours for 2 consecutive days every 5 weeks. Regarding the 11/20 dogs (55%) that had 283 
deceased at time of data capture, 3 dogs died or were euthanized because of disease 284 
progression, 6 dogs were euthanized because of acute neurological deterioration after 285 
initial neurological improvement, and 2 dogs were euthanized because of unrelated 286 
causes (complications after stifle surgery and development of aggression). Dogs that 287 
showed acute neurological deterioration after initial improvement did so within a 288 
median of 171 days after diagnosis (ranging from 30 – 669 days). Of those 6 dogs, 1 289 
dog showed acute deterioration after discontinuation of prednisolone treatment, and 5 290 
dogs were still receiving treatment consisting of prednisolone 1mg/kg every 24 hours, 291 
prednisolone 0.5mg/kg every 24 hours, prednisolone 2mg/kg every 24 hours and 292 
azathioprine 2mg/kg every 24 hours, or cytosine arabinoside 50mg/ m2 every 12 hours 293 
for 2 consecutive days every 7 weeks. Overall, we can conclude that 10/21 dogs 294 
(48%) died or were euthanized because of MMUO.  295 
No difference was seen in long-term survival between dogs receiving sole 296 
prednisolone therapy or combination therapy with cytosine arabinoside (P=0.31). 297 
Overall, the MST was 669 days (ranging from 1 – 2250 days) (Figure 3). (Deleted: 298 
There was no difference in survival time (ST) between small/medium and large breed 299 
dogs with MMUO (P=0.47) (Figure 2).) No significant difference was seen in relative 300 
lesion length on MR imaging between dogs that are alive and dogs that died or were 301 
euthanized because of MMUO (P=0.91). Post mortem confirmation was available in 3 302 
dogs, revealing GMEM in 2 dogs and necrotising meningomyelitis in 1 dog. All 303 
clinical data are summarized in tables 1 and 2. 304 
 305 
Discussion 306 
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 307 
This study evaluated the clinical presentation, diagnostic findings and long-term 308 
survival in 21 dogs diagnosed with presumptive MMUO. Dogs had a median age of 5 309 
years at time of diagnosis. A lesion affecting the T3-L3 spinal cord segments resulting 310 
in ambulatory paraparesis was considered the most common clinical presentation. 311 
However the overall MST was 669 days, 48% of dogs diagnosed with MMUO died or 312 
were euthanized because of MMUO, indicating a guarded long-term prognosis. 313 
 314 
To be included in the study, dogs were not allowed to have clinical signs or 315 
neurological examination abnormalities suggestive of intracranial involvement. 316 
Interestingly, additional MR images of the brain were included in the field of view of 317 
the cervical MRI in 2 dogs, showing additional lesions in both cases. One of those 318 
dogs, a 123-month-old Rhodesian Ridgeback, developed seizures 669 days after 319 
diagnosis despite on-going cytosine arabinoside treatment, and was therefore 320 
euthanized. No necropsy was performed, but because intracranial lesions were already 321 
present at time of diagnosis, development of MUO was assumed. The other dog, a 56-322 
month-old Jack Russell Terrier, never recovered from general anaesthesia for MR 323 
imaging. Necropsy was performed, revealing the presence of GMEM. Because 324 
intracranial MR images were only available in 2 dogs, it is currently unclear (1) if 325 
these brain abnormalities represent a multifocal nature of the disease or cranial 326 
extension of the cervical inflammatory lesions, and (2) if inflammatory brain lesions 327 
are currently underdiagnosed in dogs with MMUO and if MMUO could therefore be 328 
considered a more generalised inflammatory disease process, a 329 
meningoencephalomyelitis. 330 
 331 
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Pain on direct spinal palpation was present in 71% of dogs. Spinal pain reflects the 332 
involvement of the meninges, and/or vertebrae (vertebral periosteum), and/or nerve 333 
roots or spinal nerves (Da Costa 2012). In the present study, the lesions showed 334 
meningeal contrast enhancement in 18/21 dogs, but there was no significant 335 
association between spinal hyperaesthesia and the presence of meningeal 336 
enhancement on MR imaging.   337 
 338 
MRI of the spinal cord revealed no lesion on sagittal T2W and T1W images in 10% 339 
of dogs (n=2), which appears similar to the 7% described for the brain in dogs with 340 
MUO (Granger et al. 2010). In the retrospective study of Griffin et al. (2008), only 1 341 
dog with meningomyelitis had MRI performed, revealing no abnormalities. Based on 342 
these findings, presence of MMUO cannot be ruled out based on unremarkable MRI 343 
findings. The first dog was a 42-month-old Bull Mastiff with a one-month history of 344 
slowly progressive T3-L3 spinal cord lesion. After diagnostic procedures, the dog was 345 
treated with oral prednisolone but continued to deteriorate and was euthanized after 6 346 
days. No necropsy was performed. The second dog was a 136-month-old Bearded 347 
Collie with a one-week history of a progressive multifocal spinal cord 348 
neuroanatomical localisation (T3-S3 spinal cord lesion). The dog showed 349 
improvement on treatment with prednisolone and cytosine arabinoside (see table 1) 350 
after diagnostic investigations, and was still alive without current treatment 1100 days 351 
after diagnosis. Both dogs had inflammatory CSF analysis (increased TNCC and TP 352 
concentration). For both dogs, the presence of vascular, degenerative and neoplastic 353 
spinal cord lesions can’t be excluded. As both dogs had a progressive disease course, 354 
a vascular (ischaemic) lesion seemed less likely. A neoplastic lesion cannot be 355 
excluded, although this seems rather unlikely in the Bull Mastiff considering his very 356 
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young age. The second dog had a lymphocytic pleocytosis on CFS analysis, but no 357 
signs of lymphoma were seen on microscopical examination, however no specific test 358 
to look for clonality was performed.  359 
If a lesion was visible on MRI, all lesions were extensive, ill-defined, intramedullary, 360 
hyperintense on T2W images and isointense on T1W images. Other spinal conditions, 361 
including acute non-compressive nucleus pulposus extrusions (ANNPE) and 362 
ischaemic myelopathy (IM), are also associated with intraparenchymal 363 
hyperintensities on MRI. These conditions are however associated with other clinical 364 
and MRI characteristics, which could potentially aid in differentiating between these 365 
conditions (Cardy et al. 2015; Fenn et al. 2016). Looking into a recent study (Cardy et 366 
al. 2015), the clinical presentation of dogs with spinal cord dysfunction, IM (most 367 
commonly fibrocartilagenous embolic myelopathy (FCEM)) and ANNPE are 368 
typically characterised by a peracute onset of non-progressive clinical signs and 369 
affected dogs do not commonly demonstrate overt spinal hyperaesthesia at time of 370 
admission. This is in contrast with the clinical presentation of dogs with MMUO, 371 
which was characterised by an acute onset of progressive and mainly symmetrical 372 
neurological deficits, with pain on spinal palpation or manipulation in 86% of dogs 373 
(Cardy et al. 2015), which is comparable with the 71% of dogs presenting with spinal 374 
hyperaesthesia in the presented study. (Deleted: Typical MRI characteristics of dogs 375 
with ANNPE include a focal area of intramedullary spinal cord hyperintensity on 376 
T2W images overlying an intervertebral disc space, a reduction in volume of the T2W 377 
hyperintense nucleus pulposus signal, mild narrowing of the associated disk space, 378 
presence of extradural material or signal intensity change with minimal or no spinal 379 
cord compression at this level, and are more likely to be lateralised (De Risio et al. 380 
2015; Fenn et al. 2016). Diagnosis of IM (or presumed FCEM) is based on the 381 
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presence of a focal, relatively well-demarcated intramedullary T2W hyperintense 382 
lesion, mainly affecting grey matter, with an absence of the above criteria used to 383 
diagnose ANNPE and mainly showing no lateralization (De Risio et al. 2015; Fenn et 384 
al. 2016). In the presented study, dogs diagnosed with MMUO all showed presence of 385 
an extensive, ill-defined, intramedullary hyperintensity over multiple vertebral bodies, 386 
without concurrent presence of disk space narrowing or reduction in the nucleus 387 
pulposus signal. In a study looking at MRI findings in dogs with suspected ischemic 388 
myelopathy, contrast enhancement was seen in a small proportion of affected dogs  389 
(De Risio et al. 2007). Additionally, lesions of dogs with IM have been reported to 390 
have a median lesion to vertebral body ration of 1.6 and 2.2 for lesions in the cervical 391 
(compared to C6) and thoracolumbar region (compared to L2), respectively (De Risio 392 
et al. 2007). Compared to the present study, revealing an overall lesion/vertebral body 393 
ratio of 4.8, the lesions in dogs with MMUO seem to be remarkably longer than the 394 
intraparenchymal hyperintense lesions seen in dogs with IM or ANNPE.) Although 395 
CSF analysis in dogs with IM is most often within normal limits, affected dogs can 396 
demonstrate an increased TP concentration and mild neutrophilic or mixed cell 397 
pleocytosis with a median TNCC of 12 WBC/microL (De Risio et al. 2007). A 398 
marked pleocytosis with a median TNCC of 209 WBC/mm3 was seen in the presented 399 
study, although results should be interpreted with caution as presence of a CSF 400 
pleocytosis was considered one of the inclusion criteria. To conclude, the presentation 401 
of a dog with an acute or chronic onset of a progressive and painful T3-L3 402 
myelopathy in combination with an extensive, ill-defined, intramedullary lesion with 403 
presence of parenchymal and/or meningeal contrast enhancement on MRI, and 404 
presence of a marked pleocytosis on CSF analysis, can be presumptively diagnosed 405 
with MMUO. The importance of differentiating between these conditions is 406 
 18 
highlighted by the differences in treatment and prognosis between dogs with 407 
presumptive MMUO and dogs with ANNPE or IM. 408 
 409 
A previous study demonstrated that short tau inversion recovery (STIR) 410 
hyperintensities in the cervical epaxial musculature of dogs with 411 
meningoencephalomyelitis had a sensitivity of 78% and a specificity of 92% in 412 
predicting inflammatory CSF results (Eminaga et al. 2013). In the presented study, 413 
STIR images were unfortunately only available in 3/21 cases. Adding this sequence to 414 
the protocol in dogs with presence of a focal or multifocal, ill-defined T2W 415 
intramedullary hyperintensity might be considered in the future.  416 
 417 
Several studies have evaluated survival times of dogs diagnosed with MUO (Granger 418 
et al. 2010, Coates and Jeffery 2014). Overall, dogs with MUO appear to have a 419 
guarded prognosis. A large meta-analysis of dogs with MUO revealed an overall 420 
reported MST of 240-590 days in 96 dogs treated with corticosteroids plus any other 421 
immunosuppressive protocol, compared to a MST of 28-357 days for 43 dogs 422 
receiving corticosteroids alone (Granger et al. 2010). In the presented study, dogs 423 
with presumptive MMUO had a MST of 669 days (2 years), but ultimately, 48% of 424 
dogs died or were euthanized because of MMUO, indicating a more guarded long-425 
term prognosis.  426 
 427 
Limitations of this study are the relative small sample size and retrospective character, 428 
which limited standardisation of patient assessment and treatment. Although dogs 429 
were all treated with glucocorticosteroids, it cannot be excluded that specific 430 
differences in treatment have influenced our results. Despite including cases over a 431 
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relative large period and from a busy referral hospital, only 21 dogs could be 432 
included. This could indicate that MMUO should be considered a rare disorder and 433 
this is in agreement with previously reported findings (Cardy et al. 2015), which 434 
indicated that MMUO represents approximately 6% of all spinal disorders in dogs.  435 
 436 
Conclusion 437 
 438 
Presumptive MMUO can be diagnosed in every dog breed of every age that is 439 
presented with signs of a mainly acute or chronic, possibly painful, myelopathy. 440 
Although clinical signs can vary, affected animals most typically present with 441 
ambulatory paraparesis and ataxia, localizing to T3-L3 spinal cord segments. MRI 442 
typically reveals an extensive, ill-defined and intramedullary lesion that appears 443 
hyperintense on T2W images and isointense on T1W images. Most lesions showed 444 
parenchymal contrast enhancement and/or enhancement of the overlying meninges on 445 
post-contrast T1W images which can possibly differentiate dogs with MMUO from 446 
other more common spinal diseases. In 10% of cases, no lesion was visible on sagittal 447 
T2W and T1W images. Almost 50% of dogs died or were euthanized because of 448 
MMUO, with a MST of 669 days for all dogs. Future studies should be performed 449 
looking into intracranial imaging in dogs diagnosed with presumptive MMUO and its 450 
prognostic value, extensive infectious disease testing in all cases and outcome using a 451 
standard treatment protocol to give more information about this condition. 452 
 453 
 454 
 455 
  456 
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FIGURE LEGENDS 504 
Figure 1 505 
Figure 1: T2W transverse (left image) MR image of the vertebral column and spinal 506 
cord at the level of C3, and mid sagittal (right image) MR image of the cervical and 507 
cranial thoracic vertebral column and spinal cord of a 56-month-old Jack Russell 508 
Terrier. There is presence of a large, ill-defined, intramedullary hyperintensity 509 
extending from cranial C2 until cranial C6.  510 
 511 
Figure 2 512 
Figure 2: T2W sagittal (top image) and transverse (bottom left image), and T1W 513 
transverse (bottom right image) of the vertebral column and associated spinal cord of 514 
a 13-month-old French Bulldog. There is presence of a large, ill-defined, 515 
intramedullary lesion that is hyperintense on T2W images and isointense on T1W 516 
images. The lesion is extending from mid T10 until caudal L1.  517 
 518 
Figure 3 519 
Figure 3: Kaplan-Meier survival curve for overall survival in dogs diagnosed with 520 
MMUO. Results were censored for dogs that were still alive at time of data capture 521 
and dogs that died because of unrelated causes (single little blocks). 522 
 523 
 524 
 525 
  526 
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TABLES 527 
Table 1 528 
Table 1: Clinical details of the 21 dogs diagnosed with MMUO. FE = female entire, 529 
FN = female neutered, ME = male entire, MN = male neutered, CSF = cerebrospinal 530 
fluid, TNCC = total nucleated cell count, SC = subcutaneous, CRI = constant rate 531 
infusion, NA = not applicable, NP = not performed, GMEM = granulomatous 532 
meningoencephalomyelitis, NMEM = necrotising meningoencephalomyelitis. 533 
 534 
 24 Case Breed Gender 
Age 
(months) at 
presentation 
Clinical presentation 
Neuroanatomical 
localisation 
Spinal 
hyperesthesia 
CSF 
TNCC 
(cells/µl) 
MRI lesion Initial treatment 
Cytosine arabinoside 
dose (mg/m2), SC or CRI 
Initial 
response to 
treatment 
Long-term follow-up and treatment 
Death or 
euthanasia 
because of 
MMUO 
Overall 
ST 
(days) 
Post 
mortem 
findings 
1 Akita FE 36 Non ambul paraparesis Multifocal Yes 1740 Focal Prednisolone 2mg/kg /day 50 mg/m2 SC Improvement 
Euthasia because of acute 
deterioration after discontinuation of 
prednisolone treatment 
Yes 380 NP 
2 Rottweiler ME 123 Ataxia T3-L3 No 209 Focal Prednisolone 2mg/kg /day 50 mg/m2 SC Deterioration 
Euthanasia because of disease 
progression 
Yes 20 NP 
3 
Bull 
Mastiff 
ME 42 Ambulatory paraparesis T3-L3 Yes 6 No lesion  visible Prednisolone 2mg/kg /day No cytosine arabinoside Deterioration 
Euthanasia because of disease 
progression 
Yes 6 NP 
4 Labrador MN 105 Ambulatory paraparesis L4-S3 Yes 123 Focal Dexamethasone 0,3mg/kg/day 50 mg/m2 SC Improvement 
Euthanasia because of acute 
deterioration, was still receiving 
1mg/kg of prednisolone every day 
Yes 30 NP 
5 JRT MN 89 Ambulatory paraparesis T3-L3 No 200 Focal Prednisolone 2mg/kg /day No cytosine arabinoside Improvement 
Normal dog, still receiving 0,2 
mg/kg/day prednisolone 
No 237 NA 
6 
Lhasa 
Apso 
FE 48 Ambulatory tetraparesis C1-C5 Yes 900 Focal Prednisolone 4mg/kg /day 50 mg/m2 SC Improvement 
Euthasia because of acute 
deterioration, was still receiving 0,5 
mg/kg prednisolone per day 
Yes 171 GMEM 
7 Shih Tzu MN 50 Ambulatory tetraparesis C6-T2 Yes 5 Focal Prednisolone 2mg/kg /day 50 mg/m2 SC Improvement 
Normal dog, receiving cyclosporine 
5mg/kg/day 
No 2250 NA 
8 
Giant 
Schnauzer 
ME 32 Non ambul paraparesis Multifocal No 1345 Focal Prednisolone 2mg/kg /day 50 mg/m2 SC Improvement 
Euthanasia because of agression, was 
only receiving cytosine arabinoside 
every 5 weeks  
No 752 NP 
9 
Yorkshire 
Terrier 
FN 36 Ambulatory tetraparesis C1-C5 Yes 7 Focal Prednisolone 2mg/kg /day No cytosine arabinoside Improvement 
Euthanasia because of acute 
deterioration, was still receiving 
1mg/kg of prednisolone per day 
Yes 202 NMEM 
10 
English 
Springer 
Spaniel 
ME 85 Ataxia Multifocal No 455 Focal Prednisolone 2mg/kg /day No cytarabine Improvement 
Euthanasie because of post-operative 
infection after stifle surgery, dog 
normal and on no medication 
No 304 NP 
11 
Rhodesian 
Ridgeback 
FE 123 Normal gait C1-C5 Yes 89 Focal* Dexamethasone 0,3mg/kg/day 50 mg/m2 SC Improvement 
Euthanasie because development of 
seizures, was still receiving 
cytarabine 50mg/m2 SC every 7 
weeks 
Yes 669 NP 
12 
Bearded 
Collie 
MN 136 Ambulatory paraparesis Multifocal Yes 162 No lesion visible Prednisolone 2mg/kg /day 50 mg/m2 SC Improvement 
Normal dog, receiving no current 
treatment 
No 1100 NA 
13 Boxer ME 26 Normal gait Multifocal Yes 6000 Focal Prednisolone 2mg/kg /day 50 mg/m2 SC Improvement 
Normal dog, receiving cytarabine 
50mg/m2 SC every 9 weeks 
No 1460 NA 
14 
Lhasa 
Apso 
MN 128 Ambulatory paraparesis L4-S3 Yes 1540 Multifocal Prednisolone 2mg/kg /day 50 mg/m2 SC Stable 
Euthanasia because of disease 
progression 
Yes 33 NP 
15 Chihuahua ME 19 Ataxia T3-L3 Yes 9 Multifocal Dexamethasone 0,3mg/kg/day No cytosine arabinoside Improvement 
Normal dog, receiving no current 
treatment 
No 635 NA 
16 
Cross 
Breed 
FN 83 Ambulatory paraparesis Multifocal No 1230 Multifocal Dexamethasone 0,3mg/kg/day 200 mg/m2 CRI Improvement 
Euthanasia because of acute 
deterioration, was still receiving 
2mg/kg of prednisolone every day, 
combined with 2mg/kg azathioprine 
Yes 93 NP 
17 
French 
Bulldog 
ME 13 Ambulatory paraparesis T3-L3 No 250 Multifocal Prednisolone 2mg/kg /day No cytosine arabinoside Improvement 
Normal dog, receiving no current 
treatment 
No 791 NA 
18 
Maltese 
Terrier 
FN 104 Ataxia Multifocal Yes 95 Focal Dexamethasone 0,3mg/kg/day 50 mg/m2 SC Improvement 
Normal dog, still receiving 1mg/kg of 
prednisolone per day, and cytarabine 
50mg/m2 SC every 4 weeks 
No 577 NA 
19 
Jack 
Russell 
Terrier 
FN 56 Non ambulatory tetraparesis C6-T2 Yes 2690 Focal* Dexamethasone 0,5mg/kg/day No cytosine arabinoside 
Dog never 
recovered 
from general 
anaesthesia 
for MRI 
Dog never recovered from GA Yes 0 GMEM 
20 
French 
Bulldog 
ME 10 Non ambulatory paraparesis T3-L3 Yes 43 Focal Dexamethasone 0,3mg/kg/day 50 mg/m2 SC Improvement 
Ataxia and  ambulatory paraparesis, 
still receiving 0,5mg/kg of 
prednisolone every other day and 
cytarabine 50mg/m2 every 5 weeks 
No 90 NP 
21 
West 
Highland 
White T. 
FE 103 Non ambulatory tetraparesis Multifocal Yes 1980 Multifocal Dexamethasone 0,3mg/kg/day 50 mg/m2 SC Improvement 
Normal dog, receiving cyclosporine 
5mg/kg/day 
No 210 NA 
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Table 2 
 
Table 2: summary of the most important demographic, treatment and outcome data in 
dogs diagnosed with MMUO. IQR = interquartile range, CSF = cerebrospinal fluid, 
TNCC = total nucleated cell count,  TP = total protein, IV = intravenous, CRI = 
constant range infusion, SC = subcutaneous. 
Variable Number (%) or median (IQR) 
Signalment  
   Age (months) 56 (10 – 128) 
   Male / female 13 (62%) / 8 (38%) 
Duration of clinical signs prior 
to diagnosis (days) 
8 (1 – 90) 
Onset of neurological signs  
   Peracute 1 (5%) 
   Acute 9 (43%) 
   Chronic 11 (52%) 
Neurological examination  
   Focal / multifocal lesion 13 (62%) / 8 (38%) 
   Focal lesion localisation  
      C1-C5 3 (23%) 
      C6-T2  2 (15%) 
      T3-L3 6 (47%) 
      L4-S3 2 (15%) 
   Neurological grade  
      Grade 0 0 
      Grade 1 2 (10%) 
      Grade 2 14 (67%) 
      Grade 3 5 (24%) 
      Grade 4 0 
      Grade 5 0 
   Pain on spinal palpation 15 (71%) 
   Urinary retention 2 (10%) 
   Urinary and faecal 
incontinence 
2 (10%) 
CSF examination      
   TNCC (cells/mm3) 209 (6 – 6000) 
   TP concentration (g/l) 1.67 (0.21 – 16.3) 
Treatment     
   Glucocorticosteroids 21 (100%) 
     IV dexamethasone 9 (43%) 
     Oral prednisolone  12 (57%) 
   Cytosine arabinoside      14 (67%) 
      CRI  1 (7%) 
      SC injections 13 (93%) 
Outcome      
    Survival to discharge    20 (95%) 
    Alive at time of data capture 9 (45%) 
 
